Brought to you by 
Amicus Therapeutics raises $55mm with Series C round
05 Oct 2005
Executive Summary
Amicus Therapeutics (develops small-molecule drugs for genetic disorders) raised $55mm through a Series C financing round led by Quaker BioVentures. Also participating in the round were other new backers Palo Alto Investors and the Garden State Life Sciences Venture Fund (managed by the New Jersey Economic Development Authority), and existing shareholders Canaan Partners, CHL Medical Partners, Frazier Healthcare Ventures, New Enterprise Associates, Prospect Venture Partners, and Radius Ventures.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amicus Therapeutics raises $55mm with Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice